abstract |
The invention relates to shortened GIP analogues, which contain one or more substitutions as compared to the wild-type GIP and may have altered, preferably increased, GLP-1 activity, for example, when tested in an in vitro test for efficacy. The invention provides compounds that are dual GIP-GLP-1 agonists and related methods. |